ABBV-CLS-628

Asset

Investigational drug for autosomal dominant polycystic kidney disease

Stage
Phase 2
Modality
Small molecule
Target
Not known
1
Indication
1
Trial
1
Developer

Indications

1
  • Autosomal dominant polycystic kidney disease

    Phase 2, calicolabs.com, 10 Oct 2026

In the full profile

  • Owner and partners1
  • Trials1
  • Competitors2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets